BCAX

Bicara Therapeutics
BCAX

Overview Fund Trends Analyst Outlook Journalist POV
16.25 USD
--0.21
1.28%
At close Updated Oct 31, 4:00 PM EDT
Pre-market
After hours
16.25
0.00
0%
1 day
-1.28%
5 days
-6.07%
1 month
2.91%
3 months
46.26%
6 months
13.08%
Year to date
-4.02%
1 year
-31.38%
5 years
-30.59%
10 years
-30.59%
 

About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Healthcare Biotechnology
0
Funds holding %
of 7,505 funds
Explore Fund Trends
0
Analysts bullish %
of 2 analysts
See Analyst Outlook
–
Positive news %
of articles
Check Journalist POV
Price charts implemented using Lightweight Charts™